Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Structure Therapeutics Inc. (GPCR), a clinical-stage biopharmaceutical company focused on chronic metabolic and cardiopulmonary conditions, announced Friday positive results from Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 in healthy overweight or obese individuals.
Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced what.
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.